Comparison of the efficacy of presurgical axitinib combined with PD-1 inhibitors and axitinib in the treatment of renal cell carcinoma with tumor thrombus: a retrospective cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus (TT) is a challenging condition requiring complex surgery with significant perioperative risk. Presurgical therapy, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), may reduce thrombus burden and facilitate surgery, but comparative evidence remains limited. This study aimed to compare the efficacy of presurgical axitinib combined with PD-1 inhibitors versus axitinib alone in patients with RCC and IVC tumor thrombus. We retrospectively evaluated 40 patients with RCC and IVC tumor thrombus treated with presurgical therapy at the Department of Urology, Peking University Third Hospital from March 2019 to October 2024. Among them, 24 cases were treated with axitinib combined with pembrolizumab, tislelizumab, sintilimab, or toripalimab, and 16 cases received the axitinib. The primary endpoint was the percentage change in TT level in two groups after presurgical therapy, and the secondary outcomes included the change in IVC-TT height and RCC volume, operation results, and so on. After the presurgical therapy, the percentage of patients who had a reduction in Mayo level was 45.8% (11/24) in the axitinib with ICIs group and 18.8% (3/16) in the axitinib group ( p = 0.124). In the TT height, there were 84.2% (16/19) in the ICI/TKI group and 71.4% (10/14) in the axitinib group experiencing a reduction ( p = 0.375) while the median reduction in absolute TT length was 1.8 cm and 1.6 cm ( p = 0.439). The objective response rate (ORR) was 47.4% in the axitinib with ICIs group and 28.6% in the axitinib group ( p = 0.551). In terms of surgical results, 15 cases (68.2%) and 4 cases (25%) received a minimally invasive approach ( p = 0.009), the average operation time was 239.1 ± 91.2 and 333.1 ± 122.7 min ( p = 0.01), the median intraoperative blood loss was 550 ml and 650 ml ( p = 0.284) with the median blood transfusion volume of 400 ml and 800 ml ( p = 0.064) and the median postoperative hospital stay was 7 days and 10 days ( p = 0.312) respectively in the axitinib with ICIs group and axitinib group. Compared with presurgical axitinib therapy, presurgical combination of axitinib and PD-1 inhibitors may have the potential to reduce IVC TT level and height and achieve a higher ORR, facilitating the surgery procedure.
Source: BMC Urology
Institution: Peking University Third Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: renal cell carcinoma, inferior vena cava tumor thrombus, axitinib, PD-1 inhibitors, pembrolizumab, tislelizumab, sintilimab, toripalimab, presurgical therapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, Mayo score, minimally invasive surgery, surgical outcomes, objective response rate
Open Access status: gold
Estimated APC paid: $2,990
OpenAlex ID: W7236103429
